Next Lesson - Hypertension and Heart Failure
Core
The Adrenergic Terminal
Adrenergic pharmacology (the study of drugs acting on the adrenaline and noradrenaline system) becomes manageable when every drug is placed on one map. Most sympathetic postganglionic terminals (the endings of the nerve fibres that leave a ganglion to reach the target organ) release noradrenaline. Tyrosine enters the neurone and tyrosine hydroxylase converts it to L-DOPA (an intermediate chemical on the way to dopamine). This is the rate-limiting step, the slowest step, which sets the speed of the whole pathway. Aromatic L-amino-acid decarboxylase forms dopamine in the cytosol (the fluid inside the cell). Vesicular monoamine transporter (VMAT, a pump for monoamine transmitters such as dopamine and noradrenaline) then carries dopamine into acidic storage vesicles, where dopamine beta-hydroxylase forms noradrenaline. In adrenal chromaffin cells (the hormone-secreting cells of the adrenal medulla), phenylethanolamine N-methyltransferase can convert noradrenaline to adrenaline.
An arriving action potential opens voltage-gated calcium channels. Calcium triggers vesicle fusion and noradrenaline release. Released transmitter can activate postsynaptic adrenoceptors (the adrenaline and noradrenaline receptors on the target cell) or presynaptic alpha-2 autoreceptors (receptors on the nerve ending itself). The autoreceptor provides negative feedback: Gi signalling lowers transmitter release, partly by reducing calcium-channel activity and by making it easier for potassium to leave the cell (increasing potassium conductance).
Synthesis and release operate on different timescales. Tyrosine hydroxylase governs the supply of new catecholamines (adrenaline, noradrenaline and dopamine), but a single action potential mainly draws from transmitter already packaged in vesicles. After release, rapid NET retrieval and VMAT reloading conserve noradrenaline that would otherwise need to be rebuilt. Strong or repeated stimulation increases demand on synthesis, transport and vesicular reserve together. This distinction matters pharmacologically: inhibiting synthesis limits replacement, inhibiting VMAT limits protected storage, and blocking exocytosis prevents release despite a full vesicle.
At a sympathetic nerve junction, the main rapid termination route is neuronal reuptake through the noradrenaline transporter (NET). Recovered noradrenaline can return to vesicles through VMAT or be broken down by monoamine oxidase (MAO), an enzyme on the outer membrane of mitochondria inside the neurone. Catechol-O-methyltransferase (COMT) is important outside the neurone and in the wider metabolism of circulating catecholamines. Do not draw COMT as though it were the chief enzyme floating in the synaptic cleft (the gap between the nerve ending and its target). Reuptake ends most local noradrenergic signals; metabolism completes disposal both inside the neurone and in the tissues around it (extraneuronal compartments).
At the sympathetic junction, synthesis and vesicular recycling supply noradrenaline while NET reuptake ends most local signalling.
SimpleMed original educational diagram
Three G-protein Rules
All adrenoceptors are G-protein-coupled receptors (receptors that signal inside the cell through a G protein), but three predominant couplings organise the family. Alpha-1 is mainly Gq: phospholipase C (an enzyme that starts the calcium signal) generates inositol trisphosphate (IP3, which releases stored calcium) and diacylglycerol (DAG), intracellular calcium rises, and smooth muscle commonly contracts. Alpha-2 is mainly Gi: adenylyl cyclase (the enzyme that makes cyclic AMP, or cAMP, an intracellular messenger) activity and cAMP fall, supporting presynaptic inhibition and several postsynaptic effects. Beta-1, beta-2 and beta-3 are mainly Gs: adenylyl cyclase and cAMP rise.
The same second messenger (a chemical signal made inside the cell after a receptor is activated) does not guarantee the same organ response. In cardiac myocytes (heart muscle cells), beta-1-driven cAMP increases calcium entry and calcium cycling (calcium moving into and out of its stores with each beat), so rate, conduction and force can rise. In airway smooth muscle, beta-2-driven cAMP activates protein kinase A (an enzyme switched on by cAMP) and reduces the activity of myosin light-chain kinase (the enzyme that lets smooth muscle contract), favouring relaxation. Always combine signalling with cell type.
Memorise the predominant coupling, then ask what cAMP or calcium does in that particular cell.
SimpleMed original educational diagram
Receptor Location Predicts Effect
Alpha-1 receptors are prominent on vascular smooth muscle, the radial muscle of the iris and smooth muscle at the bladder outlet. Their Gq-calcium signal favours contraction, predicting vasoconstriction, mydriasis (pupil widening) and increased outlet tone. Alpha-2 receptors occur presynaptically and in central autonomic pathways, where activation reduces sympathetic transmitter output. They also occur postsynaptically in sites including pancreatic islets (the insulin-secreting clusters of the pancreas) and platelets, so the shorthand "presynaptic only" is unsafe.
Beta-1 receptors are important in the sinoatrial node (the heart's pacemaker), atrioventricular node (the relay between the atria and ventricles), myocardium and juxtaglomerular cells (kidney cells that release renin). Activation can increase heart rate, conduction, contractility and release of renin (a kidney enzyme that raises blood pressure). Beta-2 receptors are prominent in airway, uterine and selected vascular smooth muscle. Their Gs-cAMP pathway usually relaxes those tissues. Beta-2 activation also supports metabolic responses and drives potassium into skeletal muscle, explaining why a drug that targets beta-2 receptors to widen the airways (bronchodilation) can also produce tremor, tachycardia (fast heart rate) or hypokalaemia (low blood potassium).
Beta-3 receptors are relevant in human detrusor muscle (the bladder wall muscle), where activation favours bladder relaxation during storage. They also act in fat (adipose) tissue, although their metabolic effects in humans should not be reduced to a single memorised function. Receptor expression overlaps between tissues, so these are predictive anchors rather than exclusive addresses.
Receptor location turns a signalling pathway into an organ response; overlap explains many off-target effects.
SimpleMed original educational diagram
Direct Agonists
A direct agonist binds and activates an adrenoceptor. Phenylephrine is relatively alpha-1 selective, so vascular smooth-muscle contraction and a rise in total peripheral resistance (the overall resistance to blood flow through the body's vessels) are predictable. Clonidine and dexmedetomidine activate alpha-2 receptors; central and presynaptic inhibition explains reduced sympathetic output and sedation better than calling them general sympathetic stimulants.
Dobutamine is used as a predominantly beta-1 agonist example: direct cardiac beta-1 activation increases cAMP and calcium cycling. Salbutamol is relatively beta-2 selective: it relaxes airway smooth muscle, and when more of the drug reaches the bloodstream (systemic exposure) it can also cause tremor and a shift of potassium into cells. Mirabegron provides a beta-3 example at detrusor muscle. Adrenaline activates alpha and beta receptor families, so its net response depends on concentration, access, tissue receptor expression and the starting physiological state. Drug names are examples attached to a receptor rule, not a list to learn without mechanism.
Indirect and Mixed Sympathomimetics
An indirect sympathomimetic increases adrenergic signalling without needing to act as the main receptor agonist. One route is NET inhibition, which keeps released noradrenaline outside the neurone for longer. Another is entry through NET followed by interference with vesicular storage and outward transmitter transport. Tyramine (an amine found in some foods) and amphetamine-related mechanisms illustrate transmitter displacement and transporter-dependent release, although their detailed actions are not identical. Because these drugs depend on an intact terminal and available stores, their behaviour differs from a direct agonist applied to a denervated tissue (one that has lost its nerve supply).
Transport direction and compartment are essential. NET normally uses transmembrane ion gradients to move noradrenaline from the junction into the cytosol. VMAT then moves cytosolic monoamine into an acidic vesicle. An indirect substrate can exploit these transporters and alter the normal direction of traffic, whereas a reuptake inhibitor occupies NET and delays clearance without itself needing to empty a vesicle. Both can raise extracellular transmitter, but they reach that endpoint by different steps and will respond differently to depleted stores or transporter loss.
A mixed-acting sympathomimetic combines direct receptor activation with increased noradrenaline availability. Ephedrine is a classic teaching example. The store-dependent indirect action predicts tachyphylaxis (a response that fades with repeated doses): repeated closely spaced exposure can produce a diminishing response as readily releasable transmitter becomes less available. A purely direct agonist does not require the body's own (endogenous) noradrenaline stores to activate its receptor.
Direct drugs activate the receptor; indirect drugs raise junctional transmitter; mixed drugs use both routes.
SimpleMed original educational diagram
Adrenergic Antagonists
Antagonists reveal the same map in reverse. Alpha-1 blockade reduces smooth-muscle contraction, so vasodilation and postural hypotension follow directly from receptor location. A selective alpha-1A antagonist (alpha-1A is a subtype of the alpha-1 receptor) can reduce bladder-outlet tone with less vascular effect than a non-selective alpha-1 blocker, but subtype selectivity remains relative.
Beta antagonists differ in which receptors they cover and in extra properties, such as added alpha-1 blockade. Propranolol blocks beta-1 and beta-2 receptors, so reduced cardiac stimulation comes with loss of beta-2 airway-widening (bronchodilator) and metabolic support. Bisoprolol and metoprolol are relatively beta-1 selective at usual doses, not beta-1 exclusive. Labetalol and carvedilol combine beta blockade with alpha-1 antagonism. The clinical choice between beta blockers belongs in system pharmacology; here the key task is to predict the organ effects removed by each receptor block.
Selectivity Is Relative
Selectivity compares affinity (how tightly a drug binds a receptor) or potency (how much drug is needed for a given response) at one receptor with another. It is not a wall. At a concentration that substantially occupies a high-affinity intended target, occupancy (the proportion of receptors with drug bound) of lower-affinity receptors may still be small. As free concentration rises, lower-affinity receptors become more engaged and the clinical advantage of selectivity narrows. This is why a beta-1-selective antagonist can still block beta-2 receptors at higher concentrations. It is also why systemic salbutamol can produce cardiac or metabolic effects despite its useful beta-2 preference.
Do not turn the concept into one universal high-dose rule. Each drug has its own affinity, efficacy, distribution and active-metabolite profile. Disease can also change receptor number or physiological reserve (the spare capacity of an organ). The safe general prediction is narrower: increasing concentration usually widens receptor occupancy, so expected effects should be rechecked beyond the preferred target.
Potency, efficacy and selectivity should also remain separate. Potency asks how much drug produces a chosen response; efficacy asks the maximum response that system can produce; selectivity compares activity at different targets. On a concentration-response graph, a curve for the preferred target that sits further to the left shows potency at that receptor (a lower concentration gives the response), but says nothing about safety until the relevant off-target curve is known. Receptor reserve (spare receptors, so a full effect needs only some of them occupied) can further separate occupancy from measured effect, so the diagram below is a reasoning aid rather than a dosing chart.
Selectivity is a separation between curves, not an absolute border; higher exposure can recruit off-target receptors.
SimpleMed original educational diagram
Reflexes and Adverse Effects
A direct receptor effect can trigger an opposing reflex. Alpha-1-mediated arteriolar constriction raises total peripheral resistance and arterial pressure. Arterial baroreceptors (pressure sensors in the artery walls) then fire more, increasing vagal drive and reducing sympathetic drive to the heart. Heart rate may therefore fall even though the drug belongs to the sympathomimetic family. Conversely, beta-2-mediated vasodilation can lower resistance and recruit reflex tachycardia. The final pulse is the combined result of the direct cardiac action and the baroreflex (the reflex that adjusts heart rate to blood pressure), not a label attached to the drug class.
Mechanism also predicts adverse effects. Excess alpha-1 activation can produce hypertension and tissue ischaemia through vasoconstriction. Alpha-2 agonism can cause bradycardia (slow heart rate), hypotension, dry mouth and sedation through reduced central or peripheral sympathetic output. Beta-1 activation can cause tachycardia and arrhythmia (abnormal heart rhythm); beta-1 blockade can cause bradycardia or conduction slowing. Beta-2 activation can cause tremor, tachycardia and hypokalaemia, while beta-2 blockade can provoke bronchoconstriction (narrowing of the airways) in susceptible airways, for example in people with asthma. Mixed or indirect sympathomimetics can combine cardiovascular and central effects because they widen the transmitter signal rather than selecting one organ.
Use the same sequence every time. First locate the synapse and identify whether the action is direct or indirect. Then name the receptor and its predominant G protein, and predict the cell response. Finally add reflex compensation and the loss of selectivity at higher concentrations. That method converts adrenergic pharmacology from a drug list into a reusable physiological model and prepares the receptor framework for Hypertension and Heart Failure.
Reviewed by: Dr. Marcus Judge
- 138
